{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:23:30Z","timestamp":1791401010501,"version":"4.3.3"},"reference-count":0,"publisher":"Journal of Infection in Developing Countries","issue":"01","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Infect Dev Ctries"],"abstract":"<jats:p>Objective: To evaluate the long-term outcomes of hepatitis delta patients, including cirrhosis and hepatocellular carcinoma (HCC), based on clinical and laboratory data.\nMethodology: A retrospective evaluation was conducted on patients diagnosed with hepatitis delta. The patients were formed into four groups: no-treatment, pegylated interferon, oral antiviral, and combined treatment.\nResults: A total of 93 patients, 48 women and 45 men, were evaluated in the study. The mean follow-up time was 4.38 \u00b1 2.7 years. Of those, 43 were in the no-treatment group, 22 received combination therapy including pegylated interferon and oral antiviral treatment for chronic hepatitis B (the combined treatment group), 19 received only oral antiviral treatment for chronic hepatitis B (the oral antiviral group), and nine received pegylated interferon (the pegylated interferon group). HDV-RNA negativity was observed in 67% (6\/9) of patients in the pegylated interferon group and 33% (5\/15) of patients in the combined treatment group. HDV-RNA became spontaneously negative in one of the two patients in the no-treatment group, while no patient in the oral antiviral group became HDV-RNA negative. Seven patients were diagnosed with cirrhosis and one with HCC. Three patients had undergone liver transplants. There were no fatalities among patients.\nConclusions: Pegylated interferon therapy has been demonstrated to have partial efficacy in the treatment of delta hepatitis, while oral antivirals have been shown to offer no additional benefit. Although negative HDV-RNA was achieved in some patients treated with pegylated interferon, pegylated interferon treatment could not eliminate the risk of cirrhosis and HCC.<\/jats:p>","DOI":"10.3855\/jidc.20257","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T18:37:46Z","timestamp":1739990266000},"page":"146-154","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of the long-term outcomes of patients with hepatitis delta"],"prefix":"10.3855","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7198-4324","authenticated-orcid":false,"given":"Muhammet Salih","family":"Tarhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8406-2254","authenticated-orcid":false,"given":"Habip","family":"Gedik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2963-4894","authenticated-orcid":false,"given":"Kadriye","family":"Kart-Yasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2222","published-online":{"date-parts":[[2025,1,31]]},"container-title":["The Journal of Infection in Developing Countries"],"original-title":[],"link":[{"URL":"https:\/\/www.jidc.org\/index.php\/journal\/article\/download\/20257\/3580","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jidc.org\/index.php\/journal\/article\/download\/20257\/3580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T18:37:46Z","timestamp":1739990266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jidc.org\/index.php\/journal\/article\/view\/20257"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":0,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2025,1,31]]}},"URL":"https:\/\/doi.org\/10.3855\/jidc.20257","relation":{},"ISSN":["1972-2680"],"issn-type":[{"value":"1972-2680","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]}}}